Confident View Ahead: Infant Feeding & Formula – From Nourishment to Innovation
March 2026
Navigating Safety, Science, and the Imperative for Infant Formula Innovation.
Breastfeeding remains the gold standard of infant nutrition — but just 48% of infants worldwide are exclusively breastfed for the recommended six months. For millions of families, infant formula is not a lifestyle choice but a medical necessity. Yet innovation has slowed, recently accumulated safety and quality concerns, and operates within regulatory frameworks last substantively updated in the 1990s. The window for change is open. This edition of Confident View Ahead sets out why it must be seized.
- 48% Infants exclusively breastfed globally — below the WHO’s 50% target for 2025
- 82B Estimated global infant formula market value in 2024, growing at double-digit CAGR
- 150+ Distinct human milk oligosaccharide structures — most still absent from infant formula
What This Edition Covers
Section 1
Safety & the Regulatory Gap
From the 2022 US national shortage to a 2025 pan-European contamination event and a cluster of infant botulism cases — we document a sector where the margin for error is zero, and current oversight falls demonstrably short. The FDA Inspector General’s 2024 findings represent a call to action that governments cannot defer.
Section 2
The Science of the Gap
Human breast milk is a living biological fluid of extraordinary complexity — immunoglobulins, growth factors, over 150 human milk oligosaccharide structures, human milk proteins, and a dynamic microbiome. We map exactly where formula falls short and why that gap represents the innovation roadmap for the decade ahead.
Section 3
Innovation on the Horizon
Five-HMO blends, precision-fermented human-milk proteins, MFGM-enriched ingredients, structured lipids, and synbiotic microbiome formulations represent a credible near-term pipeline of genuine nutritional advancement — if regulatory pathways are designed to enable, not obstruct, evidence-based innovation.
Section 4
A Global Policy Stocktake
We assess Operation Stork Speed in the US, FSANZ Proposal P1028 in Australia, and the EU’s delegated regulation framework — identifying where each jurisdiction leads, where meaningful gaps remain, and the seven regulatory priorities that no major market has yet fully addressed.
The infant formula sector needs to rededicate its efforts on treating infant formula as a life-sustaining healthcare product rather than a commercial commodity. The tools, the science, and — increasingly — the regulatory momentum now exist to enable that. The question is whether industry and governments will act with the urgency this population deserves.
The CSG Perspective
Our three convictions
- Breastfeeding promotion and formula innovation are not in conflict. They are complementary public health imperatives. The same commitment to infant health that drives necessary breastfeeding support must also drive relentless improvement in formula quality, safety, and nutritional adequacy.
- The sector has underinvested in innovation relative to its commercial scale and public health obligation. The tools are available. The science is mature. What is needed is the policy environment and commercial will to act — and companies that move early will define the category.
- Information is a public health good. Restricting access to evidence-based information about infant formula — for parents or healthcare professionals who need it — does not protect infants. It exposes them to risk. Regulation must target harmful commercial promotion, not the free flow of health information.
Confident View Ahead is produced by Confident Strategy Group — strategic advisors at the intersection of policy, science, regulation, and reputation. We have worked in infant feeding and infant formula globally for over 25 years. To receive the full edition or explore how CSG can support your organisation, contact us at confidentstrategygroup.com.
Our Work >